GenSmile Rolls Out Pearl AI Across 38 UK Practices

GenSmile, one of the UK’s largest privately owned dental groups, is rolling out Pearl AI’s radiograph analysis platform across its 38-practice network. Announced on 4 June 2026, the deployment follows three years of in-practice use by clinical director Dr Asad Rahman, and scales the technology from individual sites to a group-wide standard for AI-assisted radiographic interpretation, clinical governance and patient communication. It is one of the larger AI deployments in UK dentistry to date.

Pearl AI is a dental artificial intelligence platform trained on millions of dental images, designed to flag radiographic findings such as caries, bone loss, failing restorations and calculus in real time. The platform is positioned as a clinician support tool rather than an independent diagnostic system, with all findings reviewed and validated by the treating practitioner. For a multi-site group such as GenSmile, the technology offers three concrete operational benefits: greater consistency of findings across practices, stronger clinical governance at network level, and standardised visual support for patient conversations.

GenSmile’s deployment model embeds Pearl AI across the whole practice team, including reception staff, treatment coordinators, hygienists, dentists, therapists and specialists, rather than restricting use to the clinician chairside. The intent is continuity in how AI-assisted findings are explained to patients across every interaction in their treatment journey. Dr Rahman, speaking after three years of personal use, described Pearl AI as a meaningful efficiency lever during high-volume sessions, particularly given the administrative pressure on clinicians balancing back-to-back appointments with detailed note-taking and compliance documentation.

The 38-practice rollout positions GenSmile as one of the larger UK dental groups to commit to AI-assisted radiograph review at scale. With patients increasingly expecting transparent, technology-supported clinical experiences and the wider primary care sector watching how AI clinical decision support performs at network level, expect competitive groups to accelerate their own AI evaluations through the second half of 2026.